Clinical trial
Characterization of the Physiological and the Pathological Role of Anti-C1q Autoantibodies in Pregnancy: a Potential Treatment for Pre-eclampsia to Prevent Fetal Intrauterine Growth Restriction?
NCT06317467 is registered in ClinicalTrials.gov with IRCCS Burlo Garofolo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Characterization of the Physiological and the Pathological Role of Anti-C1q Autoantibodies in Pregnancy: a Potential Treatment for Pre-eclampsia to Prevent Fetal Intrauterine Growth Restriction?
- Lead sponsor
- IRCCS Burlo Garofolo
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- September 13, 2023
- Completion date
- December 31, 2026
- Enrollment
- 54 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.